SUNY, NYU, Galderma Sue Indian Generics Pharma Lupin for Allegedly Infringing Rosacea Rx IP | GenomeWeb

By Ben Butkus

The State University of New York, New York University, and L'Oreal subsidiary Galderma Laboratories are suing Indian generic drugmaker Lupin for allegedly infringing four patents related to Oracea, Galderma's orally administered treatment for rosacea.

The suit, filed last week in the US District Court for the District of Delaware, claims that Lupin has infringed the patents by submitting an abbreviated new drug application with the US Food and Drug Administration for a generic version of Oracea.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.